CY1121847T1 - Παραγωγα 1-((3-((1-πιπεραζινυλο)καρβονυλο)φαινυλο)μεθυλο)-2,4(1η,3η)-κιναζολινοδιονης ως αναστολεις parp για τη θεραπεια του καρκινου - Google Patents

Παραγωγα 1-((3-((1-πιπεραζινυλο)καρβονυλο)φαινυλο)μεθυλο)-2,4(1η,3η)-κιναζολινοδιονης ως αναστολεις parp για τη θεραπεια του καρκινου

Info

Publication number
CY1121847T1
CY1121847T1 CY20191100769T CY191100769T CY1121847T1 CY 1121847 T1 CY1121847 T1 CY 1121847T1 CY 20191100769 T CY20191100769 T CY 20191100769T CY 191100769 T CY191100769 T CY 191100769T CY 1121847 T1 CY1121847 T1 CY 1121847T1
Authority
CY
Cyprus
Prior art keywords
quinazolinodione
piperazinyl
carbonyl
cancer
phenyl
Prior art date
Application number
CY20191100769T
Other languages
English (en)
Inventor
Ye Edward Tian
Haijun Dong
Qingbing XU
Lizhen Wu
Lijun Liu
Yangzhen JIANG
Qingli BAO
Guoxiang WANG
Feng Yin
Chengyun GU
Xiuhua HU
Xiaozhu WANG
Sishun Kang
Shengzhi CHEN
Sui Xiong Cai
Original Assignee
Impact Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN2011100824756A external-priority patent/CN102731416A/zh
Application filed by Impact Therapeutics, Inc. filed Critical Impact Therapeutics, Inc.
Publication of CY1121847T1 publication Critical patent/CY1121847T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Στο παρόν αποκαλύπτονται 1-(αρυλομεθυλο)κιναζολινο-2,4(1Η, 3Η)-διόνες, που αναπαριστούνται από τον Τύπο (I), όπου τα Ar, R1 - R6 ορίζονται στο παρόν. Οι ενώσεις που έχουν τον Τύπο (I) είναι αναστολείς της PARP. Συνεπώς, οι ενώσεις της εφεύρεσης μπορούν να χρησιμοποιηθούν για τη θεραπεία κλινικών παθήσεων που ανταποκρίνονται στην αναστολή της δράσης της PARP.
CY20191100769T 2011-04-01 2019-07-18 Παραγωγα 1-((3-((1-πιπεραζινυλο)καρβονυλο)φαινυλο)μεθυλο)-2,4(1η,3η)-κιναζολινοδιονης ως αναστολεις parp για τη θεραπεια του καρκινου CY1121847T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2011100824756A CN102731416A (zh) 2011-04-01 2011-04-01 1-(芳基甲基)-喹唑啉-2，4-二酮作为parp抑制剂及其应用
CN2011077034 2011-07-11
PCT/CN2012/073362 WO2012130166A1 (en) 2011-04-01 2012-03-31 1-(arylmethyl)quinazoline-2,4(1h,3h)-diones as parp inhibitors and the use thereof

Publications (1)

Publication Number Publication Date
CY1121847T1 true CY1121847T1 (el) 2020-07-31

Family

ID=46929484

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191100769T CY1121847T1 (el) 2011-04-01 2019-07-18 Παραγωγα 1-((3-((1-πιπεραζινυλο)καρβονυλο)φαινυλο)μεθυλο)-2,4(1η,3η)-κιναζολινοδιονης ως αναστολεις parp για τη θεραπεια του καρκινου

Country Status (19)

Country Link
US (4) US9290460B2 (el)
EP (1) EP2709990B1 (el)
JP (1) JP6270713B2 (el)
CN (2) CN104230827B (el)
AU (1) AU2012237776B2 (el)
CA (1) CA2831015C (el)
CY (1) CY1121847T1 (el)
DK (1) DK2709990T3 (el)
ES (1) ES2736299T3 (el)
HR (1) HRP20191273T1 (el)
HU (1) HUE046121T2 (el)
PL (1) PL2709990T3 (el)
PT (1) PT2709990T (el)
RS (1) RS59091B1 (el)
SG (1) SG193599A1 (el)
SI (1) SI2709990T1 (el)
TR (1) TR201910675T4 (el)
TW (1) TWI527800B (el)
WO (1) WO2012130166A1 (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9090568B2 (en) 2011-03-14 2015-07-28 Impact Therapeutics, Inc. Quinazolinediones and their use
TWI527800B (zh) 2011-04-01 2016-04-01 南京英派藥業有限公司 作為聚（二磷酸腺苷酸－核醣）聚合酶（ｐａｒｐ）之抑制劑之１－（芳基甲基）喹唑啉－２，４（１ｈ，３ｈ）－二酮及其應用
WO2013064083A1 (en) 2011-11-01 2013-05-10 Impact Therapeutics, Inc. 1-(arylmethyl)-5,6,7,8-tetrahydroquinazoline-2,4-diones and analogs and the use thereof
BR112014026266A2 (pt) 2012-04-24 2017-06-27 Chugai Pharmaceutical Co Ltd derivado de quinazolidinadiona
SG11201406860SA (en) 2012-04-24 2014-11-27 Chugai Pharmaceutical Co Ltd Quinazolinedione derivative
AU2014249003A1 (en) 2013-03-13 2015-10-15 Forma Therapeutics, Inc. Novel compounds and compositions for inhibition of FASN
CA2927830A1 (en) 2013-10-23 2015-04-30 Chugai Seiyaku Kabushiki Kaisha Quinazolinone and isoquinolinone derivative
EP3174541A1 (de) * 2014-07-28 2017-06-07 Technische Universität Dresden Thymin- und chinazolin-dion-derivate zur hemmung von hsp27
US11179392B2 (en) * 2015-04-03 2021-11-23 Impact Therapeutics, Inc. Solid pharmaceutical formulation of PARP inhibitors and use thereof
CN106083741A (zh) * 2016-02-22 2016-11-09 南京中医药大学 2‑硫代喹唑啉二酮衍生物
CN107098886B (zh) * 2016-02-26 2020-07-14 中国医学科学院药物研究所 含有哌嗪酮的喹唑啉酮类parp-1/2抑制剂及其制备方法、药物组合物和用途
WO2017156350A1 (en) 2016-03-09 2017-09-14 K-Gen, Inc. Methods of cancer treatment
EP3438096B1 (en) * 2016-04-01 2020-12-02 Impact Therapeutics, Inc Manufacturing process for 1-(arylmethyl) quinazoline-2,4 (1h, 3h)-dione
CN108727343A (zh) * 2017-04-21 2018-11-02 中国医学科学院药物研究所 含有3-氨基四氢吡咯的喹唑啉酮类parp-1/2抑制剂及其制备方法、药物组合物和用途
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
CN111269216A (zh) * 2018-12-05 2020-06-12 中国医学科学院药物研究所 含有哌嗪酮的喹唑啉二酮盐类化合物、其制备方法、药物组合物和用途
JP7370032B2 (ja) * 2019-05-14 2023-10-27 スーヂョウ フォー ヘルス ファーマスーティカルズ カンパニー リミテッド Ｐａｒｒ阻害剤としてのキナゾリン―２．４―ジオン誘導体
US20230263801A1 (en) * 2020-07-24 2023-08-24 Impact Therapeutics (Shanghai), Inc Combination therapy of parp inhibitors
WO2022099442A1 (zh) * 2020-11-10 2022-05-19 上海瑛派药业有限公司 5-氟-1-(4-氟-3-(4-(嘧啶-2-基)哌嗪-1-羰基)苄基)喹唑啉-2,4(1h,3h)-二酮的结晶形式及其制备
KR20230163467A (ko) * 2021-03-26 2023-11-30 임팩트 테라퓨틱스 (상하이), 인코포레이티드 Parp 억제제의 경구 캡슐 및 이의 제조 방법
WO2023138667A1 (zh) * 2022-01-21 2023-07-27 上海瑛派药业有限公司 Senaparib和替莫唑胺的复方制剂及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3989816A (en) 1975-06-19 1976-11-02 Nelson Research & Development Company Vehicle composition containing 1-substituted azacycloheptan-2-ones
DE2652144A1 (de) * 1976-11-16 1978-05-18 Merck Patent Gmbh Neue chinazolindione
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
CA1161036A (en) 1980-05-15 1984-01-24 Masayuki Ishikawa Quinazoline-dione compounds, process for production thereof and pharmaceutical use thereof
MX7829A (es) 1986-08-21 1993-08-01 Pfizer Quinazolindionas y piridopirimindionas y procedimiento para su preparacion
DE69622148T2 (de) 1995-09-28 2002-10-31 Suntory Limited, Osaka Chinazozin derivate und deren verwendung
US6201121B1 (en) 1995-12-28 2001-03-13 Fuji Chemical Industry Co., Ltd. Process for the preparation of 3-dihalobenzyl-2,4-quinazolinedione derivatives
AU1743997A (en) 1996-12-20 1998-07-17 Geron Corporation Poly(adp-ribose) polymerase inhibitors to treat diseases associated with cellular senescence
AUPO440496A0 (en) 1996-12-30 1997-01-23 Fujisawa Pharmaceutical Co., Ltd. Quinazoline derivatives
CA2283514A1 (en) 1997-03-17 1998-09-24 Fujisawa Pharmaceutical Co., Ltd. Process for producing quinazoline derivatives
JP2001302515A (ja) 2000-04-18 2001-10-31 Sumitomo Pharmaceut Co Ltd ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤
JP2002284699A (ja) 2001-03-28 2002-10-03 Sumitomo Pharmaceut Co Ltd 視細胞変性疾患治療剤
JP2005501021A (ja) * 2001-06-19 2005-01-13 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 抗細菌剤
DE10201240A1 (de) 2002-01-15 2003-07-24 Bayer Ag Substituierte Alkyluracile und ihre Verwendung
CN1980913B (zh) 2004-06-30 2011-12-14 詹森药业有限公司 作为parp抑制剂的喹唑啉二酮衍生物
JP2007137818A (ja) * 2005-11-17 2007-06-07 Taisho Pharmaceut Co Ltd ８−ヒドロキシ−２，４（１ｈ，３ｈ）−キナゾリンジオン誘導体
JP5323063B2 (ja) 2007-05-31 2013-10-23 塩野義製薬株式会社 オキシイミノ化合物およびその使用
GB0716532D0 (en) 2007-08-24 2007-10-03 Angeletti P Ist Richerche Bio Therapeutic compounds
JP5464609B2 (ja) 2008-03-27 2014-04-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ チューブリン重合阻害剤としてのキナゾリノン誘導体
US20140018376A1 (en) * 2009-10-20 2014-01-16 Hans Allgeier Use of 1H-Quinazoline-2,4-Diones
US9090568B2 (en) * 2011-03-14 2015-07-28 Impact Therapeutics, Inc. Quinazolinediones and their use
TWI527800B (zh) 2011-04-01 2016-04-01 南京英派藥業有限公司 作為聚（二磷酸腺苷酸－核醣）聚合酶（ｐａｒｐ）之抑制劑之１－（芳基甲基）喹唑啉－２，４（１ｈ，３ｈ）－二酮及其應用

Also Published As

Publication number Publication date
ES2736299T3 (es) 2019-12-27
TR201910675T4 (tr) 2019-08-21
PL2709990T3 (pl) 2020-03-31
US20190270732A1 (en) 2019-09-05
US10316027B2 (en) 2019-06-11
AU2012237776A1 (en) 2013-10-10
CA2831015C (en) 2020-03-24
SI2709990T1 (sl) 2019-09-30
DK2709990T3 (da) 2019-07-29
WO2012130166A1 (en) 2012-10-04
CA2831015A1 (en) 2012-10-04
US20180215741A1 (en) 2018-08-02
CN104230827B (zh) 2016-10-26
JP2014509615A (ja) 2014-04-21
JP6270713B2 (ja) 2018-01-31
AU2012237776B2 (en) 2016-09-15
US11358955B2 (en) 2022-06-14
US20140023642A1 (en) 2014-01-23
HRP20191273T1 (hr) 2019-10-18
EP2709990A1 (en) 2014-03-26
CN103097361A (zh) 2013-05-08
HUE046121T2 (hu) 2020-02-28
PT2709990T (pt) 2019-07-24
RS59091B1 (sr) 2019-09-30
CN104230827A (zh) 2014-12-24
TWI527800B (zh) 2016-04-01
US9926304B2 (en) 2018-03-27
EP2709990B1 (en) 2019-06-12
EP2709990A4 (en) 2014-11-26
SG193599A1 (en) 2013-10-30
US9290460B2 (en) 2016-03-22
CN103097361B (zh) 2014-08-06
US20160237070A1 (en) 2016-08-18
TW201245161A (en) 2012-11-16

Similar Documents

Publication Publication Date Title
CY1121847T1 (el) Παραγωγα 1-((3-((1-πιπεραζινυλο)καρβονυλο)φαινυλο)μεθυλο)-2,4(1η,3η)-κιναζολινοδιονης ως αναστολεις parp για τη θεραπεια του καρκινου
CY1121625T1 (el) Αναστολεις prmt5 και χρησεις αυτων
CY1120534T1 (el) Μακροκυκλικοι αναστολεις παραγοντα χια συμπυκνωμενοι με ετεροκυκλους
EA201890594A1 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
EA201001848A1 (ru) Производные пиразина в качестве блокаторов эпителиальных натриевых каналов
EA201590277A1 (ru) Дигидропиридон р1 в качестве ингибиторов фактора xia
EA201691302A1 (ru) Новые гетероциклические соединения
MX2015012431A (es) Pirrol amida como inhibidores.
EA201591913A1 (ru) Ингибиторы протеинкиназы
CU24039B1 (es) Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
EA201991884A2 (ru) Ингибиторы g12c kras
CR20140413A (es) Inhibidores de serina/treonina cinasa
EA201170872A1 (ru) Ингибиторы протеинкиназы
MX2009012418A (es) Derivados de quinazolin-oxima como inhibidores de hsp90.
EA201590281A1 (ru) Новые гетероарильные и гетероциклические соединения, их композиции и способы
PH12017501160A1 (en) 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis
ATE517107T1 (de) Pyrrolopyrazinkinaseinhibitoren
EA201070864A1 (ru) Новые гетероциклические соединения
ATE522509T1 (de) Pyrimidylcyclopentane als inhibitoren der akt- proteinkinase
SV2009003233A (es) Derivados de 2-(1-fenil -5- hidroxi -4alfa-metil-hexahidrociclopenta (f)indazol-5- il)etil fenilo como ligandos del receptor glucocorticoide
MY170922A (en) Dihydro-benzo-oxazine and dihydro-pyrido-oxazine derivatives
WO2014031438A3 (en) SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS
EA201291217A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ПРОИЗВОДНЫЕ 1-(β-D-ГЛЮКОПИРАНОЗИЛ)-2-ТИЕНИЛМЕТИЛБЕНЗОЛА КАК ИНГИБИТОРЫ НЗПГ
EA201170722A1 (ru) Лактамы в качестве ингибиторов бета-секретазы
EA201591360A1 (ru) Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств